Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability - Poll - MDSpire

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability

  • By

  • Xing Zhou

  • Xi’an Xiong

  • Zhen Yang

  • Zhongping Cao

  • Qianxi Ni

  • July 3, 2026

  • 0 min

Share

Original Source(s)

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability

  • by Xing Zhou, Xi’an Xiong, Zhen Yang, Zhongping Cao, Qianxi Ni

  • July 3, 2026

Related Content

Imaging-mediated genetic effects link brain microstructure, metabolic profiles, and regional transcription to glioma susceptibility

Commentary: PCP4 inhibits the progression of prostate cancer through Ca2+/CAMKK2/AMPK/AR pathway

Dynamic changes in serum albumin, prealbumin, and retinol-binding protein after head and neck cancer surgery: a retrospective cohort study